BDRX Biodexa Pharmaceuticals Plc stock chart & analysis
Conviction 25Scan · Wed, Nov 4, 2026Biodexa Pharmaceuticals Plc (BDRX) closed at $2.79 (-1.06%) on Nov 4, 2026. Its latest daily candle is a bearish marubozu. Price is below its 50-day and below its 200-day moving average. RSI(14) 35, RS Rating 1, -99.1% from its 52-week high, -96.5% year to date.
Why BDRX moved
From the StockSetups movers recaps that covered BDRX, newest first. A recap states what was known that day.
- Close+96.9%
Biodexa published its interim results for the six months ended June 30, 2026 on September 11 (via Yahoo Finance). The filing also surfaced in Friday's pre-market healthcare movers lists on Benzinga and in a broader roundup of European ADRs trading higher on US exchanges.
Top Stock Movers Today — September 11, 2026: Why BDRX, ACVA and FTFT Surged →
BDRX technical analysis
Trend
BDRX is in a downtrend: price is below the 50-day, which is below the 200-day moving average. It closed 46.0% below the 50-day ($5.16) and 87.7% below the 200-day ($22.73). ADX(14) at 21 points to a moderate trend. It meets 0 of 8 trend-template criteria.
Momentum
RSI(14) is 35, in the bearish half of its range. The MACD histogram is positive. Its RS Rating of 1 puts its weighted 12-month performance ahead of about 1% of the US market.
Volume and volatility
Volume on the latest session ran 0.1× its 20-day average. It trades about $1.9M a day on average. ATR(14) is $0.5886, 21.1% of price — its typical daily range. On-balance volume is trending up. Chaikin Money Flow (-0.09) shows distribution.
Key levels
The 52-week range is $2.70 to $316.94; price is 99.1% below the high and 3.5% above the low. The VWAP anchored at the 52-week high is $19.26, above price.
Performance
BDRX returned -32.6% (1 week), -41.4% (1 month), -76.3% (3 months), -92.1% (6 months), -98.7% (1 year), -96.5% (year to date).
About Biodexa Pharmaceuticals Plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
Listed 2015 · 11 employees
SEC filings
EDGAR filings in BDRX · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.